MBXBF (Microbix Biosystems) Other Long-Term Liabilities: $0.19 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBXBF Microbix Biosystems Inc MBXBF
53 GF Score
Price $0.23
GF Value $0.17
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Microbix Biosystems Other Long-Term Liabilities?

Microbix Biosystems MBXBF +3.73% 53 Other Long-Term Liabilities is $0.19 Mil as of Mar. 2026. GuruFocus rates MBXBF with a GF Score™ of 53/100 and a GF Value™ of $0.17 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Microbix Biosystems's other long-term liabilities for the quarter that ended in Mar. 2026 was $0.19 Mil.

Microbix Biosystems's quarterly other long-term liabilities increased from Sep. 2025 ($-0.00 Mil) to Dec. 2025 ($0.00 Mil) and increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.19 Mil).

Microbix Biosystems's annual other long-term liabilities declined from Sep. 2023 ($0.22 Mil) to Sep. 2024 ($-0.00 Mil) but then increased from Sep. 2024 ($-0.00 Mil) to Sep. 2025 ($-0.00 Mil).

Microbix Biosystems Other Long-Term Liabilities Related Terms

Microbix Biosystems Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Microbix Biosystems's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbix Biosystems Other Long-Term Liabilities Chart

Microbix Biosystems Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.22 -0.00 -0.00

Microbix Biosystems Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.20 -0.00 0.00 0.19
MBXBF
53GF Score
Microbix Biosystems Inc MBXBF
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microbix Biosystems Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.19 Mil mean?
Microbix Biosystems (MBXBF) has a Other Long-Term Liabilities of $0.19 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Microbix Biosystems and its competitors.
Is Microbix Biosystems' Other Long-Term Liabilities too high?
Microbix Biosystems' current Other Long-Term Liabilities is $0.19 Mil. Overall, Microbix Biosystems has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' Other Long-Term Liabilities compare to VRTX and REGN?
Microbix Biosystems' Other Long-Term Liabilities of $0.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current Other Long-Term Liabilities is $0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.17, compared to a current price of $0.23 — trading 34.2% above its estimated fair value. The current Other Long-Term Liabilities is $0.19 Mil. Microbix Biosystems' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current Other Long-Term Liabilities is $0.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microbix Biosystems (MBXBF) Overvalued in 2026?

Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued. The current stock price of $0.23 is trading 34.2% above its estimated GF Value™ of $0.17. GuruFocus considers Microbix Biosystems to be Significantly Overvalued.

Key valuation signals for MBXBF:

  • Other Long-Term Liabilities: $0.19 Mil
  • GF Value™: $0.17 vs. price of $0.23 (34.2% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microbix Biosystems Business Description

Other Exchanges MBX:Canada
Address 265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
53GF Score

Get the complete analysis for MBXBF

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price
$0.17
GF Value